CME Learning Center

Lymphoma

Real-World Evidence of CAR T-cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) CME / ABIM MOC A database study suggests that older patients with diffuse large B-cell lymphoma need more accessible, effective, and tolerable therapy.
Blood, September 2023
Relapsed/Refractory Mantle Cell Lymphoma: How Would You Care for These Virtual Patients? CME / ABIM MOC Did you know that multiple treatment options are available for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of therapy?
Medscape Education Oncology, September 2023
Hematology Half-Time Report: Bispecific Antibodies for the Treatment of Follicular Lymphoma CME / ABIM MOC Do you know how to reduce the risk of cytokine release syndrome when treating with a bispecific antibody?
Medscape Education Oncology, July 2023
Updates From the 2023 Summer Meetings: B-Cell Malignancies CME / ABIM MOC / CE Do you know the most recent clinical updates in B-cell malignancies? The latest clinical trial results are reviewed here.
Medscape Education Oncology, June 2023
Lymphoma Clinic: Approaches to the Management of Relapsed/Refractory Follicular Lymphoma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma CME / ABIM MOC How would you manage these patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)?
Medscape Education Oncology, June 2023
Clinical Decision-Making in Relapsed/Refractory Mantle Cell Lymphoma: Test Your Skills CME / ABIM MOC Did you know that there are multiple treatment options available in the third-line setting for relapsed/refractory (R/R) mantle cell lymphoma (MCL)?
Medscape Education Oncology, June 2023
Hematology Half-Time Report: Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma CME / ABIM MOC Do you know what adverse events of concern to watch for when using bispecific antibodies?
Medscape Education Oncology, June 2023
Nursing Perspectives: Best Practices in Follicular Lymphoma Management CE Rapidly changing treatment options for follicular lymphoma require oncology nurses to have the most current information. Are you prepared?
Medscape Education Oncology, June 2023
Hematology Half-Time Report: Overview of the Current Role of Bispecific Antibodies for Hematologic Malignancies CME / ABIM MOC Do you know what toxicities to watch for in patients being treated with bispecific antibodies?
Medscape Education Oncology, May 2023
Hodgkin Lymphoma: Considering Toxicities When Developing the Treatment Plan CME / ABIM MOC / CE How well do you take into account the long-term complications of treatment when planning care for your patients with Hodgkin lymphoma?
Medscape Education Oncology, May 2023
Let's Talk Relapsed/Refractory Chronic Lymphocytic Leukemia: Expert Perspectives on Reversible BTK Inhibitors CME / ABIM MOC Did you know studies have shown that noncovalent BTK inhibitors are efficacious in patients with covalent BTK inhibitor-pretreated CLL?
Medscape Education Oncology, April 2023
Relapsed/Refractory Mantle Cell Lymphoma: Where Do Novel BTK Inhibitors Fit for Our Patients? CME Have you heard about the newest noncovalent Bruton tyrosine kinase (BTK) inhibitor that has been added to the selection of BTK inhibitors used to treat relapsed/refractory (R/R) mantle cell lymphoma (MCL)?
Medscape Education Oncology, March 2023
Continuing the Conversation: Elevating Equity in Caring for Patients With Hematologic Malignancies CME / ABIM MOC / CE How confident are you at recognizing and addressing inequities in the care of patients with hematologic malignancies?
Medscape Education Oncology, March 2023
Let's Talk Specifics! B-Cell Malignancies and the Emerging Role of Bispecific Antibodies CME / ABIM MOC Looking for updates on the latest in bispecific antibodies in B-cell non-Hodgkin lymphoma (NHL)? Join for expert analysis to incorporate these novel agents into practice.
Medscape Education Oncology, March 2023
BTK Inhibitors for CLL and MCL: What the Latest Data Mean for Our Patients CME / ABIM MOC Did you know noncovalent BTK inhibitor therapy is now an option for patients with pretreated MCL who fail a prior covalent BTK inhibitor therapy?
Medscape Education Oncology, March 2023
Myeloma, Lymphoma, and Benign Hematology CME / ABIM MOC / CE Expand your knowledge and skills by exploring the latest data in myeloma, lymphoma, and benign hematology.
Medscape Education Oncology, February 2023
Waldenstrӧm Macroglobulinemia: Current and Emerging Approaches for the Community Hematologist/Oncologist CME / ABIM MOC Do you know how to personalize treatment for your patient with Waldenstrӧm macroglobulinemia?
Medscape Education Oncology, February 2023
Mantle Cell Lymphoma: Exploring the Feasibility of Moving BTK Inhibitors to the Frontline CME / ABIM MOC Do you know the latest data on Bruton tyrosine kinase (BTK) inhibitors in the frontline treatment of mantle cell lymphoma (MCL)?
Medscape Education Oncology, January 2023
Updates for the Community Provider From New Orleans: BTK Inhibitors in B-Cell Malignancies CME / ABIM MOC What was the big news out of New Orleans on BTK inhibitors: which to use, and is autologous stem cell transplantation still needed?
Medscape Education Oncology, January 2023
The New Climate of Bruton Tyrosine Kinase Inhibitors: Winter Meeting Effects on the Management of CLL and MCL CME / ABIM MOC Did you know that the second-generation Bruton tyrosine kinase (BTK) inhibitors will likely be the new standard of care when used as monotherapy?
Medscape Education, December 2022

Dare to Compare: How Well Do You Know CLL? CME / ABIM MOC / CE
Medscape Education Clinical Briefs, September 30, 2022
Can Motivational Interviewing via Text Affect Physical Activity in Pediatric Cancer Survivors? CME / ABIM MOC / CE
Medscape Education Clinical Briefs, July 29, 2022
What Factors Contribute to Risk for Secondary Cancer in Adolescent and Young Adults? CME / ABIM MOC / CE
Medscape Education Clinical Briefs, June 17, 2022
Do COVID-19 Outcomes Differ for Stem Cell Transplant Patients? CME / ABIM MOC / CE
Medscape Education Clinical Briefs, May 7, 2021
What Is the Most Common Cause of Death for Hodgkin Lymphoma Survivors? CME / ABIM MOC / CE
Medscape Education Clinical Briefs, December 28, 2020

CME Learning Center

Lymphoma

Latest Clinical Briefs

About Lymphoma

Further Reading